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Abstract The aim of this study was to assess the effects of
any anti-adhesion barrier gel used after operative hysterosco-
py for treating infertility associated with uterine cavity abnor-
malities. Gynecologists might use any barrier gel following
operative hysteroscopy in infertile women for decreasing de
novo adhesion formation; the use of any barrier gel is associ-
ated with less severe de novo adhesions and lower mean
adhesion scores. Nevertheless, infertile women should be
counseled that there is at the present no evidence for higher
live birth or pregnancy rates. There is a lack of data for the
outcome miscarriage. Preclinical studies suggest that the use
of biodegradable surgical barriers may decrease postsurgical
adhesion formation. Observational studies in the human report
conflicting results. We searched the Cochrane Menstrual Dis-
orders and Subfertility Specialized Register (10 April 2013),
the Cochrane Central Register of Controlled Trials (The
Cochrane Library2013, Issue 1), MEDLINE (1950 to 4 April
2013), EMBASE (1974 to 4 April 2013), and other electronic
databases of trials including trial registers, sources of unpub-
lished literature, and reference lists. We handsearched the
Journal of Minimally Invasive Gynecology (from 1 January
1992 to 13 April 2013); we also contacted experts in the field.
We included the randomized comparisons between any anti-
adhesion barrier gel versus another barrier gel, placebo, or no
adjunctive therapy following operative hysteroscopy. Primary
outcomes were live birth rates and de novo adhesion forma-
tion at second-look hysteroscopy. Secondary outcomes were
pregnancy and miscarriage rates, mean adhesion scores, and
severity of adhesions at second-look hysteroscopy. Two au-
thors independently assessed eligible studies for inclusion and
risk of bias, and extracted data. We contacted primary study
authors for additional information or other clarification. Five
trials met the inclusion criteria. There is no evidence for an
effect favoring the use of any barrier gel following operative
hysteroscopy for the key outcomes of live birth or clinical
pregnancy (risk ratio (RR) 3.0, 95 % confidence interval (CI)
0.35 to 26, P=0.32, one study, 30 women, very low quality
evidence); there were no data on the outcome miscarriage.
The use of any gel following operative hysteroscopy de-
creases the incidence of de novo adhesions at second-look
hysteroscopy at 1 to 3 months (RR 0.65, 95% CI 0.45 to 0.93,
P=0.02, five studies, 372 women, very low quality evidence).
The number needed to treat to benefit is 9 (95 % CI 5 to 33).
The use of auto-cross-linked hyaluronic acid gel in women
undergoing operative hysteroscopy for fibroids, endometrial
polyps, or uterine septa is associated with a lower mean
adhesion score at second-look hysteroscopy at 3 months
(mean difference (MD) −1.44, 95 % CI −1.83 to −1.05,
P<0.00001, one study, 24 women; this benefit is even larger
in women undergoing operative hysteroscopy for intrauterine
adhesions(MD −3.30, 95 % CI −3.43 to −3.17, P<0.00001,
one study, 19 women). After using any gel following opera-
tive hysteroscopy, there are more American Fertility Society
1988 stage I (mild) adhesions (RR 2.81, 95 % CI 1.13 to 7.01,
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P=0.03, four studies, 79 women). The number needed to treat
to benefit is 2 (95 % CI 1 to 4). Similarly there are less’
moderate or severe adhesions’ at second-look hysteroscopy
(RR 0.25, 95 % CI 0.10 to 0.67, P=0.006, four studies, 79
women). The number needed to treat to benefit is 2 (95 %CI 1
to 4) (all very low quality evidence). There are some concerns
for the non-methodological quality. Only two trials included
infertile women; in the remaining three studies, it is not clear
whether and how many participants suffered from infertility.
Therefore, the applicability of the findings of the included
studies to the target population under study should be
questioned. Moreover, only one small trial studied the effects
of anti-adhesion barrier gels for the key outcome of pregnan-
cy; the length of follow-up was, however, not specified. More
well-designed and adequately powered randomized studies
are needed to assess whether the use of any anti-adhesion
gel affects the key reproductive outcomes in a target popula-
tion of infertile women.
Keywords Adhesion prevention . Barrier gel . Operative
hysteroscopy . Infertility . Systematic review .Meta-analysis
Background
Intrauterine adhesions (IUAs) are fibrous strings at opposing
walls of the uterus. The spectrum of IUA formation may vary
from minimal IUAs to the complete obliteration of the uterine
cavity. The causes of IUAs are multifactorial; nearly 90 % of
cases are associatedwith postpartum or postabortion dilatation
and curettage. The role of infection in the development of
IUAs is controversial with the exception of genital tuberculo-
sis [1]. The pathophysiology and the mechanisms of tissue
repair in the endometrium are moreover poorly understood
despite several theories on the source of cells for human
endometrial regeneration [2].
IUA formation is the major long-term complication of
operative hysteroscopy in women of reproductive age
(Fig. 1). According to a randomized controlled trial (RCT)
on the effectiveness of preoperative treatment before operative
hysteroscopy, the incidence of postsurgical IUAs at second-
look hysteroscopy is 3.6 % after polyp removal, 6.7 % after
resection of uterine septa, 31.3 % after removal of a single
fibroid, and 45.5% after resection of multiple fibroids [3]. The
investigators of a prospective cohort study in 163 women
undergoing operative hysteroscopy conclude that the duration
of the endometrial wound healing differs according to the type
of pathology treated [4]. At follow-up hysteroscopy 1 month
after the surgical intervention, significantly more women
achieve a full healing of the endometrial cavity after removal
of endometrial polyps (32 of 37 women or 86 %) compared to
hysteroscopic lysis of intrauterine adhesions (30 of 45 women
or 67 %), treatment of uterine septum (three of 16 women or
19 %), or removal of submucous fibroids (12 of 65 women or
18 %) (P<0.05). Significantly more de novo IUAs are detect-
ed in women undergoing septoplasty (14 of 16 women or
88 %) or adhesiolysis (34 of 45 women or 76 %) compared to
removal of submucous fibroids (26 of 65 women or 40 %) or
endometrial polyps (zero of 37 women or 0 %). Women with
de novo IUAs are less likely to achieve full endometrial
wound healing within 1 month compared with those without
de novo IUAs (23 of 74 women or 31 % versus 54 of 89
women or 61 %, P=0.0003). The authors conclude that the
full recovery of the endometrium varies from 1month after the
removal of polyps to between 2 and 3 months following
hysteroscopic myomectomy [4].
Intrauterine adhesions may cause poor reproductive out-
come. Firstly, according to a large review of observational
studies, 922 of 2,151 women with IUAs (43 %) suffer from
infertility [5]. The hypothetical underlying mechanisms for
infertility due to IUAs are obstruction of sperm transport into
the cervix, impaired embryo migration within the uterine
cavity, or failure of embryo implantation due to endometrial
insufficiency [1]. Secondly, recurrent miscarriage is often
associated with IUAs; the prevalence of IUAs in women
suffering from this health problem ranges from 5 to 39 %
according to a narrative review of observational studies [6].
Thirdly, the hysteroscopic treatment of severe IUAs may
cause long-term major obstetrical complications, such as pla-
centa accreta/increta and higher risks for preterm delivery,
uterine rupture, and postpartum hysterectomy [1].
Hyaluronic acid or hyaluronan (HA) is a water-soluble
polysaccharide: It consists of multiple disaccharide units of
glucuronic acid andN-acetylglucosamine, bound together by a
β1-3-type glucoside bond. Solutions of HA have interesting
viscoelastic properties which have led to interests in develop-
ing applications of HA in surgical procedures, for example in
eye surgery. HA is not an ideal substance for all procedures,
due to its limited residence time when applied to a
surgical site. It quickly enters the systemic circulation
and is cleared rapidly by catabolic pathways. Attempts
to use hyaluronan for preventing postsurgical adhesions
have therefore been met with variable success. Several
chemically modified derivatives of HA have been de-
veloped to circumvent the disadvantages of HA. One such
derivative is auto-cross-linked polysaccharide (ACP). It is
formed by cross-linking hyaluronan, by direct formation of
covalent ester bonds between hydroxyl and carboxyl groups
of the hyaluronan molecule. ACP can be prepared with vari-
ous degrees of cross-linking, which allows tailoring of the
viscosity properties of ACP gels [7]. Carboxymethylcellulose
(CMC) is a high molecular weight polysaccharide that has a
viscosity greater than Dextran 70. CMC can be used for
adhesion prevention as a membrane barrier or a gel as a
mixture of chemically derivative sodium hyaluronate and
carboxymethylcellulose gel (HA–CMC) [8].
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The ideal anti-adhesion barrier following operative hyster-
oscopy would be the application of a biologically active
mechanical separator that achieves the suppression of intra-
uterine adhesion formation and promotes the healing of the
endometrial tissue. The use of the biodegradable gel surgical
barriers is based on the principle of keeping the adjacent
wound surfaces as mechanically separate [7]. Several preclin-
ical studies in various animal models report the effectiveness
of both ACP [9–16] and HA–CMC gels [8, 17] or HA-CMC
membranes [18, 19] for preventing postsurgical adhesions.
Other preclinical studies in animal models suggest that HA
gel remains in situ for more than 5 to 6 days [20, 21].
Similarly, animal studies demonstrate the persistence of HA–
CMC for about 7 days after its application [22]. However,
most of these studies were done in rodent models, and not in
nonhuman primate models with reproductive anatomy similar
to humans, like the baboon, a validated model for endometri-
osis research [23]
The exact mechanisms by which ACP and HA–CMC
are able to reduce adhesion reformation are not well
known, but may be related to “hydroflotation” or
“siliconizing” effects. One French clinical controlled
trial (N=54 women) studied the effectiveness of the
application of ACP gel (n=30) versus no gel (n=24)
at the end of an operative hysteroscopic procedure for
treating fibroids, polyps, uterine septa, or IUAs; there
are no statistically significant differences for the rate of
adhesion formation, the mean adhesion scores, or the
severity of the adhesions between both comparison
groups [24]. No data are available for the reproductive
outcome.
The health burden associated with infertility, abdominal
pain, or bowel obstruction due to adhesions is substantial [7,
25, 26]; the total cost of adhesion-related morbidity in the US
Health Care system exceeds $1 billion annually [27]. To the
best of our knowledge, no economical studies on adhesion
prevention after operative hysteroscopy have been conducted
in an infertile population.
Postoperative de novo adhesion formation is a determining
factor influencing endometrial wound healing [4]. At the
present, there is uncertainty whether the use of anti-adhesion
barrier gels following operative hysteroscopy affects the preg-
nancy or live birth rates; this is the main objective of the
present systematic review.
Methods
Two reviewers independently searched the Cochrane Men-
strual Disorders and Subfertility Specialized Register (10
April 2013), the Cochrane Central Register of Controlled
Trials (The Cochrane Library 2013, Issue 1), MEDLINE
(1950 to 4 April 2013), and EMBASE (1974 to 4 April
2013) using a combination of both index and free-text terms.
We used no language restrictions. We searched other electron-
ic databases of trials including trial registers, sources of un-
published literature, and reference lists. We handsearched the
Journal of Minimally Invasive Gynecology (from 1 January
1992 to 13 April 2013) and contacted experts in the field.
We included only studies that were clearly randomized or
claimed to be randomized. Studies were selected if the source
population included women of reproductive age suffering
from infertility, bound to undergo operative hysteroscopy for
suspected or unsuspected intrauterine pathology before spon-
taneous conception or any infertility treatment. Infertility was
defined as “a disease of the reproductive system defined by
the failure to achieve a clinical pregnancy after 12 months or
more of regular unprotected sexual intercourse” [28]. Studies
were excluded if infertility was explicitly reported among the
exclusion criteria.
We included the following types of randomized compari-
sons: any anti-adhesion barrier gel versus placebo, no barrier
gel, or another type of barrier gel following operative hyster-
oscopy. We did not include studies of other anti-adhesion
therapies, such as the use of human amnion membrane
grafting, insertion of a balloon catheter or IUD, or hormonal
treatment; this review focuses exclusively on the effectiveness
of anti-adhesion barrier gels.
We selected live birth and de novo adhesion formation at
second-look hysteroscopy as primary outcomes. Live birth
was defined as a delivery of a live fetus after 20 completed
weeks of gestational age that resulted in at least one live baby
Fig. 1 Intrauterine adhesions
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born. The delivery of a singleton, twin, or multiple pregnancy
was counted as one live birth [28]. Ongoing or clinical preg-
nancy, miscarriage, and mean adhesion scores or severity of
adhesions at second-look hysteroscopy were secondary out-
comes. Ongoing pregnancy was defined as a pregnancy sur-
passing the first trimester or 12 weeks of pregnancy; clinical
pregnancy was defined as a pregnancy diagnosed by US
visualization of one or more gestational sacs or definitive
clinical signs of pregnancy [28]. There are at the present seven
reported classification systems for scoring the extent or sever-
ity of intrauterine adhesions [1]. Some classification systems
have incorporated menstrual and obstetric history [29–31];
others rely exclusively on the hysteroscopic evaluation of
the uterine cavity [32–35]. None of these systems has been
validated or universally accepted [1].We avoided pooling data
from studies using different scoring systems.
One reviewer screened the titles and abstracts from the
search to remove the publications which were obviously irrel-
evant for the research question of the present systematic
review. After removing duplicates and after linking multiple
reports of the same study together, two reviewers indepen-
dently assessed the studies by examining the full text reports.
This was done without blinding them to the reviewers; studies
that appeared to be eligible were included using a pretested
data extraction form. We contacted the authors of the primary
study report whenever additional information was required.
For studies with multiple study reports, we used the main trial
report as the primary data extraction source.
Two reviewers independently assessed the risk of bias of
the included studies and across studies by using the Cochrane
“Risk of bias” tool. The following six items were assessed:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome
assessors, selective outcome reporting, and other potential
sources of bias. Any disagreements between the reviewers
for the selection, data extraction, or risk of bias assessment
were resolved through arbitration by a third author; any resid-
ual disagreement was reported in the final review.
We used the numbers of events in the comparison
groups of each study to calculate the Mantel–Haenszel
risk ratios (RR) for the binary data for all the main
outcomes; for the secondary outcome “adhesion scores,”
the mean values and the standard deviations (SD) were
used to calculate the inverse variance mean differences
(MD) and the 95 % confidence intervals (CI). We used
the most recently updated Review Manager 5 software
provided by the Cochrane Collaboration for all the
calculations, including the 95 % CI.
All main outcomes were expressed as per woman random-
ized. Multiple live births and multiple pregnancies were
counted as one event. We did not attempt to pool any
reported data that did not allow a valid analysis, such as
“per cycle” data.
We aimed to analyze the data on an intention-to-treat basis
(ITT).We tried to obtain as frequently as possible missing data
after contacting the primary study authors. If missing data
could not be obtained, we undertook imputation of individual
values for the primary outcomes only by assuming that live
births or de novo adhesions would not have occurred in
participants without a reported primary outcome. For all other
main outcomes, we used an available data analysis. We sub-
jected any imputation of missing data for the primary out-
comes to sensitivity analyses; any substantial difference in the
imputed ITT analyses compared to available data analyses
was incorporated in the interpretation of the study findings
and the discussion.
Meta-analysis was done to provide a meaningful summary
whenever enough studies which were sufficiently similar with
respect to the clinical and methodological characteristics were
available. A formal assessment of statistical heterogeneity was
done by using the Q statistic and the I2 statistic; the combina-
tion of both tests is more sensitive to detect the likelihood of
substantial statistical heterogeneity. A low P value of the Q
statistic (P<0.10) means significant heterogeneous results
among individual studies. The I2 statistic describes the per-
centage of variation across studies that is caused by substantial
statistical heterogeneity rather than random chance variation;
an I2 statistic >50 % is the cutoff above which substantial
statistical heterogeneity might be present. If there was evi-
dence of substantial heterogeneity, we aimed to explore possi-
ble explanations for this observed heterogeneity by performing
sensitivity analyses using Review Manager 5 software.
Publication bias, reporting bias, and within-study reporting
bias are difficult to detect and correct for. We aimed to do the
search for eligible studies as comprehensively as possible and
by being alert in identifying duplicated reports of trials in
order to minimize the potential impact of reporting and pub-
lication bias. Since we retrieved only a limited number of
studies, we did not study publication bias or other forms of
small study effects by creating a funnel plot.
One reviewer entered the study data and carried out the
statistical analysis using Review Manager 5. We considered
the outcomes live birth and pregnancy to be positive outcomes
of effectiveness and by consequence higher numbers of these
events as a benefit. The outcomes miscarriage, de novo adhe-
sion formation, and adhesion scores were on the contrary
considered as negative outcomes and higher numbers as harm-
ful. We planned to combine data from primary studies in a
meta-analysis with ReviewManager 5 using the risk ratio as a
summary outcome measure using a random-effects model if
enough studies were retrieved and after significant clinical
diversity and substantial statistical heterogeneity were confi-
dently ruled out.
We planned to carry out subgroup analyses according to the
extent or the severity of the uterine abnormality treated and for
studies that reported both “live birth” and “pregnancy” in order
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to assess any overestimation of the treatment effect.We planned
to do sensitivity analyses for the primary outcomes to investi-
gate whether the results and conclusions are robust to arbitrary
decisions regarding the eligibility and analysis. These sensitiv-
ity analyses included consideration whether conclusions would
have differed if the eligibility was restricted to studies without
high risk of bias versus all studies or if alternative imputation
strategies were adopted, e.g., using odds ratio rather than risk
ratio for the summary effect measure or a fixed effect rather
than a random effects as the analysis model.
Findings
Description of studies
Results of the search
We identified 203 citations from searching electronic databases.
These were combined with 2,826 additional records from other
resources. We screened 3,029 records for duplicates by using
End Note Web 3.5 and removed 2,823 duplicate citations. The
remaining 206 records were assessed for eligibility through
checking the titles and/or abstracts. We excluded 76 records
as being obviously irrelevant. The remaining 130 full-text
articles were assessed for eligibility. We retrieved 14 potentially
eligible randomized studies; we included five trials, six trials
were excluded, and three are ongoing. See Fig. 2 for the
PRISMA flow chart of the search and selection process.
Included studies
Study design and setting Five single-center parallel group
RCTs were included in the present systematic review: Four
were conducted in Italy [36–39] and one in Israel [40]. All five
trials used two comparison groups.
Only one trial [38] reported a statistical power calculation
for one of the primary outcomes (incidence of de novo adhe-
sion formation). The protocol of all included trials was ap-
proved by the Institutional Review Board. The protocol of the
trial from Israel [40] was registered in a clinical trial registry
(see NCT01377779 in Clinical Trials.gov). None of the trials
reported on funding or other potential conflicts of interest.
Participants Two of the four Italian trials included infertile
women: 34 women out of 92 participants [36] and 21 out of
110 participants [38]. The characteristics and data from these
infertile women were not available for individual patient data
meta-analysis. In the remaining two studies including 60
women [37] and 138 women [39], it is not clear whether and
how many participants suffered from infertility. Regrettably
we could not obtain any further clarification from the study
authors. The study from Israel included 30 women who were
trying to conceive after miscarriage; the proportion of women
suffering from infertility was, however, not reported, and this
could not be clarified either [40].
Three of the four Italian trials [36, 38, 39] were conducted in
the same university hospital; several co-authors participated in
the clinical research of all these trials. The in- and exclusion
criteria were very similar in these three studies; one trial includ-
ed only women with intrauterine adhesions [36]; the other trials
included women with fibroids, polyps, or uterine septa [39] or
women with single or multiple intrauterine lesions except in-
trauterine adhesions or suffering from dysfunctional uterine
bleeding [38]. The description of the source population was
not adequate in the fourth Italian study [37]. The fifth included
study was conducted in a source population of women with
retained products of conception after miscarriage [40].
The mean age of the participants was below 35 years in one
study [36]. In two trials, the mean patient age in both com-
parison groups was above 35 years [38, 39]. The other two
studies reported a range between 18 and 65 years [37] or 18
and 50 years [40] without reporting data on the mean ages and
SD in both comparison groups.
Interventions Five trials studied the randomized comparison
between the intrauterine application of an anti-adhesion gel
and no gel following operative hysteroscopy. In three studies,
auto-cross-linked hyaluronic acid gel was used [36, 37, 39];
the other two [38, 40] used polyethylene oxide–sodium car-
boxymethylcellulose gel for the intervention. In three trials,
the gel was administered into the uterine cavity through one of
the flow channels of the resectoscope; the procedure was
judged to be adequate when under hysteroscopic control the
gel seemed to have replaced the liquid medium, filling the
cavity from the fundus to the internal ostium of the cervix [36,
38, 39]. In one of these three studies [36], ultrasonographic
data demonstrated that the anti-adhesive gel was able to keep
the uterine walls separated for at least 72 h. In one study [37],
the gel was applied using the cannula in a blind way without
using hysteroscopic vizualization; for another trial [40], the
method of application of the anti-adhesion gel is not clear.
Outcomes The primary outcome of live birth was reported in
none of the included studies; the incidence of de novo adhe-
sions was reported in all five studies [36–40]. The following
secondary outcomes were reported as follows: clinical preg-
nancy [40], mean adhesion scores [36, 39], and severity of the
adhesions [36–40]. The definition of pregnancy and the time
period during which this secondary outcome was assessed in
one trial [40] was not described. Four studies [36, 38–40] used
the 1988 American Fertility Society (AFS) classification sys-
tem for scoring intrauterine adhesions at second-look hyster-
oscopy; one trial [37] used the ASRM modified scoring
system. None of these two classifications has been validated
since to the best of our knowledge neither of them has been
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directly linked to reproductive outcome. In all five studies, the
incidence and the severity of adhesion formation outcomes
were measured at one time point only, ranging from 4 to
12 weeks after the operative hysteroscopy [36–40].
Risk of bias in included studies
Allocation (selection bias)
We judged four of the five trials to be at low risk for selection
bias related to random sequence generation [36–39]. One trial
[40] did not describe the method of random sequence gener-
ation; no further clarification could be obtained. We judged all
five studies to be at unclear risk for selection bias related to
allocation since they did not adequately describe the method
of allocation concealment [36–40].
Blinding (performance bias and detection bias)
In all five trials, the method of blinding of the outcome
assessors was not described [36–40]. We judged this risk of
bias item to be important for the outcomes incidence of de
novo adhesions, mean adhesion scores, and severity of adhe-
sions but less relevant for the outcomes of live birth, ongoing
or clinical pregnancy, and miscarriage unless the follow-up
period was not long enough.
Incomplete outcome data (attrition bias)
We judged four trials to be at low risk for attrition bias [36,
38–40]. We judged one study to be at high risk for attrition
bias related to incomplete outcome data; the loss to follow-up
in this study of 33 % (20 out of 60 enrolled women) is
Fig. 2 Study flow diagram
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sufficiently high and thus very likely to cause substantial
attrition bias [37].
Selective outcome reporting (reporting bias)
We judged all trials to be at low risk of reporting bias; no
evidence for selective outcome reporting was retrieved in any
of the included studies when comparing abstract, methods,
and results section [36–40].
Other potential sources of bias
We judged three studies to be at low risk for other potential
sources of bias [36, 38, 39]. We judged one study to be at an
unclear risk for other potential sources of bias [40]; the other
study [37] was judged to be at high risk of bias due to likely
imbalance of patient characteristics, imbalanced distribu-
tion of co-treatment, and other methodological study
flaws (Figs. 3 and 4).
Effects of interventions
Any gel versus no gel
Primary outcomes
1. Live birth
There were no data for this primary outcome.
2. Incidence of de novo adhesion formation at second-
look hysteroscopy
The use of any gel following operative hysteros-
copy decreases the incidence of de novo adhesions
(RR 0.65, 95 % CI 0.45 to 0.93, P=0.02, five studies,
372 women). There is no evidence for substantial
statistical heterogeneity (chi2=7.31, df=7 (P=0.40);
I2=4 %) (Fig. 5). The number needed to treat for a
benefit is 9 (95 % CI 5 to 33).
Secondary outcomes
3. Pregnancy
There is no evidence for an effect in favor of the
use of polyethylene oxide–sodium carboxymethylcel-
lulose gel following operative hysteroscopy for
suspected retained products of conception for the
outcome of clinical pregnancy (RR 3.00, 95 % CI
0.35 to 25.68, P=0.32, one study, 30 women) (Fig. 6).
4. Miscarriage
There were no data for this secondary outcome.
5. Other secondary outcomes
(a) Mean adhesion score at 3 months inwomenwith
fibroids, polyps, or uterine septa
The use of auto-cross-linked hyaluronic acid
gel in women undergoing operative hysterosco-
py for myomas, endometrial polyps, or uterine
septa is associated with a lower mean adhesion
score at second-look hysteroscopy at 3 months
(MD −1.44, 95 % CI −1.83 to −1.05,
P<0.00001, one study, 24 women). There is no
evidence for substantial subgroup differences
(chi2=0.24, df=2 (P=0.88), I2=0 %) (Fig. 7).
(b) Mean adhesion score at 3 months in women
with intrauterine adhesions
There are statistically significant differences
in the lower mean adhesion scores at second-
look hysteroscopy at 3 months in women under-
going operative hysteroscopy for intrauterine
adhesions after the use of auto-cross-linked
hyaluronic acid gel compared to operative hys-
teroscopy only (MD −3.30, 95 % CI −3.43 to
−3.17, P<0.00001, one study, 19 women)
(Fig. 8).
(c) Severity of adhesions at second-look hysteros-
copy when using any gel
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Fig. 3 Risk of bias summary: review authors’ judgments about each risk
of bias item for each included study
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At second-look hysteroscopy, there are more
mild adhesions when using any gel following
operative hysteroscopy (RR 2.81, 95 % CI 1.13
to 7.01, P=0.03, four studies, 79 women). There
is evidence for moderate statistical heterogeneity
(chi2=12.30, df=3 (P=0.006); I2=76 %)
(Fig. 9). The number needed to treat to benefit
is 2 (95 % CI 1 to 4).
There is an effect favoring the use of any gel
following operative hysteroscopy for the out-
come of AFS 1988 stage II (moderate) adhe-
sions at second-look hysteroscopy (RR 0.26,
0.09 to 0.80, P=0.02, three studies, 58 women).
There is no evidence for substantial statistical
heterogeneity (chi2=1.43, df=2 (P=0.49); I2=
0 %) (Fig. 10). The number needed to treat to
benefit is 2 (95 % CI 1 to 2).
There is no evidence for a beneficial effect in
favor of any gel versus no gel following operative
hysteroscopy for the outcome of AFS 1988 stage
III (severe) adhesions at second-look hysteroscopy
(RR 0.46, 95 % CI 0.03 to 7.21, P=0.58, three
studies, 58 women) (Fig. 11). For the composite
outcome “moderate or severe adhesions,” there are
statistically significant differences favoring the use
of any gel following operative hysteroscopy (RR
0.25, 95 % CI 0.10 to 0.67, P=0.006, four studies,
79 women). There is no evidence for statistical
heterogeneity (chi2=1.02, df=3 (P=0.80); I2=
0 %) (Fig. 12). The number needed to treat to
benefit is 2 (95 % CI 1 to 4).
Subgroup analyses Since no data were available for the out-
come live birth, no subgroup analyses across studies reporting
live birth and pregnancy rates or only one of these two key
outcomes were done to assess any overestimation of treatment
effect. There were enough data available to conduct a sub-
group analysis according to the type of pathology treated by
operative hysteroscopy. The use of any gel following opera-
tive hysteroscopy for fibroids (RR 0.44, 95 % CI 0.17 to 1.14,
P=0.09, two studies, 80 women), endometrial polyps (RR
0.32, 95% CI 0.07 to 1.49, P=0.15, two studies, 109 women),
uterine septa (RR 0.26, 95 % CI 0.05 to 1.35, P=0.11, two
studies, 29 women), intrauterine adhesions (RR 0.44, 95 % CI
0.18 to 1.05, P=0.06, one study, 84women), retained products
of conception (RR 0.91, 95 % CI 0.57 to 1.45, P=0.69, one
study, 30 women), or “not specified” (RR 0.87, 95 % CI 0.33
to 2.29, P=0.78, one study, 40 women) consistently tends to
decrease the incidence of de novo adhesions at second-look
hysteroscopy; the differences were nevertheless not statistical-
ly significant given the limited numbers of women included
and the limited numbers of events (Fig. 5). This is a common
problem for subgroup analyses, and we should therefore be
cautious about the interpretation of the data of this sensible
predefined subgroup analysis. There is no evidence for sub-
stantial subgroup differences (chi2=5.69, df=5 (P=0.34), I2=
12.2 %).
Sensitivity analyses A sensitivity analysis was done to study
the impact of the study quality on the direction and magnitude
of the treatment effect. If we excluded the single study at high
risk of bias [37] in a sensitivity analysis, the use of any gel
following operative hysteroscopy was still beneficial for de-
creasing the incidence of de novo adhesions, but the treatment
effect was larger (RR 0.56, 95% CI 0.35 to 0.90, P=0.02, four
studies, 332 women); there is no evidence for substantial
statistical heterogeneity (chi2=7.39, df=6 (P=0.29); I2=
19%) nor for substantial subgroup differences in the subgroup
analysis according to the type of pathology treated (chi2=
5.36, df=4 (P=0.25), I2=25.4 %).
A sensitivity analysis to study the influence of the analysis
model for data synthesis (fixed effect rather than random-
effects model) did not influence the treatment effect (RR
0.55, 95 % CI 0.38 to 0.79, P=0.001, five studies, 372
women). The choice of the summary effect measure
(RR rather than OR) did not influence the treatment
effect (OR 0.40, 95 % CI 0.23 to 0.70, P=0.001, five
studies, 372 women).
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of outcome assessment (detection bias): outcome: live birth or pregnancy
Blinding of outcome assessment (detection bias): outcome: adhesions
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Fig. 4 Risk of bias graph: review
authors’ judgments about each
risk of bias item presented as
percentages across all included
studies
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Study or Subgroup
4.1.1 Myomas
Di Spiezio Sardo 2011
Guida 2004
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.72); I² = 0%
Test for overall effect: Z = 1.68 (P = 0.09)
4.1.2 Polyps
Di Spiezio Sardo 2011
Guida 2004
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
4.1.3 Septa
Di Spiezio Sardo 2011
Guida 2004
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)
4.1.4 Adhesions
Acunzo 2003
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
4.1.5 Retained products of conception
Pansky 2011
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
4.1.6 Not specified
De Iaco 2003
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 7.31, df = 7 (P = 0.40); I² = 4%
Test for overall effect: Z = 2.35 (P = 0.02)
Test for subgroup differences: Chi² = 5.69, df = 5 (P = 0.34), I² = 12.2%
Events
1
4
5
0
2
2
0
1
1
6
6
10
10
5
5
29
Total
16
25
41
22
34
56
6
8
14
43
43
15
15
18
18
187
Events
3
8
11
0
6
6
3
3
6
13
13
11
11
7
7
54
Total
15
24
39
20
33
53
7
8
15
41
41
15
15
22
22
185
Weight
2.7%
10.9%
13.7%
5.4%
5.4%
1.6%
3.1%
4.7%
16.0%
16.0%
47.1%
47.1%
13.1%
13.1%
100.0%
M-H, Random, 95% CI
0.31 [0.04, 2.68]
0.48 [0.17, 1.39]
0.44 [0.17, 1.14]
Not estimable
0.32 [0.07, 1.49]
0.32 [0.07, 1.49]
0.16 [0.01, 2.64]
0.33 [0.04, 2.56]
0.26 [0.05, 1.35]
0.44 [0.18, 1.05]
0.44 [0.18, 1.05]
0.91 [0.57, 1.45]
0.91 [0.57, 1.45]
0.87 [0.33, 2.29]
0.87 [0.33, 2.29]
0.65 [0.45, 0.93]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours any gel Favours no gel
Fig. 5 Any anti-adhesion gel
versus no gel, outcome 2:
incidence of de novo adhesions at
second-look hysteroscopy
Study or Subgroup
Pansky 2011
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Events
3
3
Total
15
15
Events
1
1
Total
15
15
Weight
100.0%
100.0%
M-H, Random, 95% CI
3.00 [0.35, 25.68]
3.00 [0.35, 25.68]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours no gel Favours any gel
Fig. 6 Any anti-adhesion gel
versus no gel, outcome 3:
pregnancy
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Discussion
Summary of main results
This systematic review aimed to appraise critically whether
the use of anti-adhesion barrier gels following operative hys-
teroscopy for suspected or unsuspected intrauterine pathology
in women of reproductive age suffering from infertility made a
difference to the main outcomes of live birth, incidence of de
novo adhesion formation, pregnancy, miscarriage, mean ad-
hesions scores, or severity of adhesions at second-look hys-
teroscopy. We searched for RCTs on anti- adhesion barrier
gels versus other barrier gels, placebo, or no anti-adhesion
barrier gels following operative hysteroscopy.
We critically appraised five studies comparing the use of
any anti-adhesion gel versus no gel in women of reproductive
age treated by operative hysteroscopy for fibroids, polyps,
septa, adhesions, or retained products of conception [36–40].
We judged a statistical pooling of the results of these five
studies to be sensible given that substantial clinical diversity
and statistical heterogeneity could confidently be ruled out.
According to our meta-analysis, there is evidence for an
effect in favor of using anti-adhesive gel following operative
hysteroscopy for decreasing the incidence of de novo
adhesions at second-look hysteroscopy. By doing a predefined
subgroup analysis, the consistency of this beneficial effect for
this outcome could be demonstrated across different sub-
groups according to the type of pathology treated. The bene-
ficial treatment effect for decreasing de novo adhesions at
second-look hysteroscopy is robust as demonstrated by mul-
tiple sensitivity analyses evaluating the influence of study
quality, choice of the analysis model for data synthesis, and
the choice of the summary effect measure.
The use of auto-cross-linked hyaluronic acid gel in women
undergoing operative hysteroscopy for fibroids, endometrial
polyps, uterine septa, or intrauterine adhesions is associated
with a lower mean adhesion score at second-look hysterosco-
py at 3 months.When de novo adhesion formation is observed
at second-look hysteroscopy, there are more mild adhesions
and less moderate or severe adhesions by using any anti-
adhesion gel after operative hysteroscopy.
There is no evidence for a treatment effect favoring the use
of polyethylene oxide–sodium carboxymethylcellulose gel
versus no gel in women treated by operative hysteroscopy
for suspected retained products of conception for the outcome
of pregnancy [40]. Although there was a beneficial trend when
using the anti-adhesion gel, the differences between both
comparison groups were not statistically significant. This
Study or Subgroup
1.3.1 Myomas
Guida 2004
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.55 (P = 0.01)
1.3.2 Polyps
Guida 2004
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.48 (P < 0.00001)
1.3.3 Septa
Guida 2004
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.98 (P = 0.05)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.24, df = 2 (P = 0.88); I² = 0%
Test for overall effect: Z = 7.22 (P < 0.00001)
Test for subgroup differences: Chi² = 0.24, df = 2 (P = 0.88), I² = 0%
Mean
2.25
2
4
SD
0.5
0.1
0.1
Total
4
4
2
2
1
1
7
Mean
3.5
3.5
5.33
SD
1.19
0.54
1.15
Total
8
8
6
6
3
3
17
Weight
16.7%
16.7%
74.5%
74.5%
8.9%
8.9%
100.0%
IV, Random, 95% CI
-1.25 [-2.21, -0.29]
-1.25 [-2.21, -0.29]
-1.50 [-1.95, -1.05]
-1.50 [-1.95, -1.05]
-1.33 [-2.65, -0.01]
-1.33 [-2.65, -0.01]
-1.44 [-1.83, -1.05]
ACP gel No gel Mean Difference Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours ACP gel Favours no gel
Fig. 7 Auto-cross linked
hyaluronic acid gel versus no gel,
outcome 5.1: mean adhesion
score AFS 1988 at 3 months in
women with myomas, polyps, or
uterine septa
Study or Subgroup
Acunzo 2003
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 47.91 (P < 0.00001)
Mean
2
SD
0.1
Total
6
6
Mean
5.3
SD
0.2
Total
13
13
Weight
100.0%
100.0%
IV, Random, 95% CI
-3.30 [-3.43, -3.17]
-3.30 [-3.43, -3.17]
ACP gel No gel Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours ACP gel Favours no gel
Fig. 8 Auto-cross linked hyaluronic acid gel versus no gel, outcome 5.2: mean adhesion score AFS 1988 at 3 months in women with intrauterine
adhesions
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may be a type II error: To detect a difference between both
comparison groups of 13 % in the clinical pregnancy rate with
a statistical power of 80 % at a confidence level of 95 % (α=
0.05 and β=0.20), a sample size of 145 women would be
needed instead of the much smaller number of 30 participants
in this single center study. We refer to Table 1 for a summary
of findings for the key outcomes clinical pregnancy and
incidence of de novo adhesions at second-look hysteroscopy
(Table 1).
Overall completeness and applicability of evidence
The evidence of the effectiveness of using any anti-adhesion
gel versus no gel in women of reproductive age treated by
operative hysteroscopy for fibroids, polyps, septa, or intrauter-
ine adhesions is limited: No data on live birth, pregnancy, or
miscarriage rates were retrieved. In women of reproductive
age treated by operative hysteroscopy for retained products of
conception, the use of polyethylene oxide–sodium carboxy-
methylcellulose gel tends to increase the clinical pregnancy
rate; the differences between both comparison groups were
not statistically significant due to the small statistical power of
the trial. Moreover, the proportion of the women suffering
from infertility in both comparison groups was not reported,
and the trial was at high risk of bias.
There are at the present two ongoing trials on the use of
anti-adhesion barrier gels after operative hysteroscopy. The
first is a parallel group randomized study on the effectiveness
of applying Oxiplex/AP Gel (Intercoat) for preventing intra-
uterine adhesions in women aged 18 to 50 years following
hysteroscopic surgery. This study is at the present not yet
recruiting [41]. The second trial will address the effectiveness
of hyaluronic acid gel in women older than 18 years following
hysteroscopic surgery; this trial will not answer the research
question in the present review since the primary and only
outcome measured is the patient satisfaction rate 2 months
after the gel application [42].
The applicability of the evidence retrieved is questionable;
most trials were conducted in a target population including—
but not limited to—women suffering from infertility: Two
trials [36, 38] included variable proportions of women suffer-
ing from infertility, miscarriage, or risk of preterm delivery;
for two studies [37, 39], it is unclear whether and how many
participants suffered from infertility while the fifth study [40]
included a source population of women with proven fertility
trying to conceive after miscarriage. It is unlikely that the
mechanisms whereby any of the studied interventions might
decrease de novo adhesion formation might differ in infertile
versus fertile target populations; nevertheless, we judge the
overall applicability of the retrieved best available evidence in
a more general source population to a target population of
women suffering from infertility to be limited at the best.
Quality of the evidence
We graded the evidence for the randomized comparison
between any anti-adhesion barrier versus no gel fol-
lowing operative hysteroscopy for the outcome of
pregnancy as very low. For this outcome, only one
small study [40] was retrieved with few events. There
are some methodological limitations: It is unclear
whether and how allocation concealment and blinding
of the outcome assessment were done in this study.
Although lack of blinding of outcome assessors may
Study or Subgroup
Acunzo 2003
Di Spiezio Sardo 2011
Guida 2004
Pansky 2011
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.60; Chi² = 12.30, df = 3 (P = 0.006); I² = 76%
Test for overall effect: Z = 2.22 (P = 0.03)
Events
6
2
6
9
23
Total
6
3
7
10
26
Events
3
1
4
8
16
Total
13
12
17
11
53
Weight
26.4%
12.9%
26.8%
33.9%
100.0%
M-H, Random, 95% CI
3.71 [1.47, 9.42]
8.00 [1.04, 61.52]
3.64 [1.47, 9.04]
1.24 [0.82, 1.88]
2.81 [1.13, 7.01]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours no gel Favours any gel
Fig. 9 Any anti-adhesion gel
versus no gel, outcome 5.3: AFS
1988 stage I (mild) adhesions at
second-look hysteroscopy
Study or Subgroup
Acunzo 2003
Di Spiezio Sardo 2011
Guida 2004
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.43, df = 2 (P = 0.49); I² = 0%
Test for overall effect: Z = 2.36 (P = 0.02)
Events
0
1
1
2
Total
6
3
7
16
Events
10
8
13
31
Total
13
12
17
42
Weight
17.2%
45.7%
37.0%
100.0%
M-H, Random, 95% CI
0.10 [0.01, 1.40]
0.50 [0.10, 2.60]
0.19 [0.03, 1.17]
0.26 [0.09, 0.80]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours any gel Favours no gel
Fig. 10 Any anti-adhesion gel
versus no gel, outcome 5.3: AFS
1988 stage II (moderate)
adhesions at second-look
hysteroscopy
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be less relevant for an unequivocal outcome such as
pregnancy, there might be some potential for risk of
bias especially since the length of the follow-up period
was not adequately described. The women included in
this study were treated by operative hysteroscopy for
retained products of conception following miscarriage;
the proportion and the characteristics of individual
women suffering from infertility were not described.
The confidence intervals for the point effect estimate
were moreover very wide. Formal study of reporting
bias was not possible since only one study was re-
trieved for this outcome; this implies that reporting
bias cannot be confidently ruled out.
For the outcome of incidence of de novo adhesions
at second-look hysteroscopy, we graded the evidence as
very low. We retrieved five studies in 372 women
[36–40]. It was unclear whether and how allocation
concealment and blinding of the outcome assessment
were done in all studies. Lack of blinding of the out-
come assessors is very relevant for this outcome since
the interpretation of the presence and the hysteroscopic
appearance of intrauterine adhesions is to some degree
subjective. One study had serious methodological limi-
tations due to high risk of attrition bias [37]. Less than
50 % of the participants of two of the five included
studies were infertile women [36, 38] whereas it is
unclear whether and how many women from the other
three studies [37, 39, 40] suffered from infertility; this
questions the applicability of the retrieved evidence in a
more general source population including but not limit-
ed to women suffering from infertility to a target pop-
ulation of infertile women only. Although we could not
formally investigate reporting bias given the small num-
ber of included studies, only studies demonstrating a
beneficial effect were retrieved. Therefore, we judged
that there might be some potential for reporting bias.
Potential biases in the review process
Our group published a Cochrane review on the effectiveness of
hysteroscopy in the treatment of female infertility associated with
suspected major uterine cavity abnormalities [43]. Given our
prior knowledge of potentially eligible studies, there might have
been some potential for detection bias. We therefore aimed to
conduct a comprehensive search strategy for the new clinical
research question of the present systematic review; this has
resulted in finding more studies than would have been detected
using the previously developed search strategy.
Agreements and disagreements with other studies or reviews
Two reviews support the use of anti-adhesive gel for reducing
de novo adhesion formation following operative hysterosco-
py. The first review [1] is a narrative review reporting the
results and conclusions of one randomized trial included in the
present systematic review [36]. The second review [44] is a
systematic review and meta-analysis studying the effective-
ness of auto-cross-linked hyaluronan gel for adhesion preven-
tion in laparoscopic and hysteroscopic surgery. The data of
three RCTs included in the present systematic review [36, 37,
39] were pooled: The proportion of women with adhesions at
second look was significantly lower in women who received
auto-cross linked hyaluronan gel than in the control group of
women undergoing operative hysteroscopy without ACP gel
Study or Subgroup
Acunzo 2003
Di Spiezio Sardo 2011
Guida 2004
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
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0
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3
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Weight
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100.0%
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Not estimable
0.46 [0.03, 7.21]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
Favours any gel Favours no gel
Fig. 11 Any anti-adhesion gel
versus no gel, outcome 5.3: AFS
1988 stage III (severe) adhesions
at second-look hysteroscopy
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Pansky 2011
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 3 (P = 0.80); I² = 0%
Test for overall effect: Z = 2.76 (P = 0.006)
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Weight
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0.10 [0.01, 1.40]
0.36 [0.07, 1.82]
0.19 [0.03, 1.17]
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0.25 [0.10, 0.67]
Any gel No gel Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours any gel Favours no gel
Fig. 12 Any anti-adhesion gel
versus no gel, outcome 5.3: AFS
1988 stage II (moderate) or stage
III (severe) adhesions at second-
look hysteroscopy
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(RR 0.50, 95 % CI 0.31 to 0.85, P=0.009, three studies, 256
women). The authors used an older methodological tool (the
Jadad scale) for assessing the validity of the included trials. The
“scale” methodology is at the present no longer supported by
the Cochrane Collaboration which recommends using a more
formal assessment by means of the risk of bias tool. This
different methodology explains the discrepancy between the
statement of Mais et al. [44] that all the included trials in their
systematic review were judged to be of a high quality which
contrasts with our judgment of “very low quality evidence” for
the outcomes of pregnancy and incidence of de novo adhesions.
One French small comparative study (n=54 women with
uterine pathology) studied the efficacy of auto-cross-linked
hyaluronic acid gel in the prevention of adhesions following
operative hysteroscopy [24]. Immediately after hysteroscopic
surgery, the target population was divided by a non-random
process into two groups: In group A, 30 women were treated
by the intrauterine application of hyaluronic acid gel whereas
the women in group B received no additional treatment (24
women). The key outcomes were the rate of adhesion forma-
tion, the mean adhesion score, and the adhesion severity
according to the AFS classification, measured by second-
look hysteroscopy 2 months after surgery. There are no sta-
tistically significant differences for the rate of intrauterine
adhesion formation between the two groups (33.3 % for
groups A and B) nor for the median adhesion scores (1.30±
2.35 versus 1.42±2.47, P>0.05) nor for the severity of the
adhesions (70 % stage I adhesions, 20 % stage II adhesions,
and 10 % stage III adhesions compared to 62.5 % stage I,
25 % stage II, and 12.5 % stage III in groups A and B,
respectively, P>0.05). The authors conclude that the use of
auto-cross-linked hyaluronic acid gel does not reduce the
incidence and the severity of intrauterine adhesions after
hysteroscopic surgery. According to a more recent review of
the literature [45]—with the first author of the French com-
parative study [24] as co-author—the majority of the limited
published studies until 2008 only evaluated the anatomic
efficiency of anti-adhesion agents after hysteroscopic surgery.
The authors conclude that the available data for the key
reproductive outcomes are not sufficiently convincing to pro-
mote the widespread clinical use of anti-adhesive barrier
agents as an effective treatment strategy for infertile women
treated by operative hysteroscopy, hence their conclusion that
additional randomized controlled trials are needed.
Authors’ conclusions
Implications for practice
Gynecologists should counsel their patients that intrauterine
adhesion formation is the major long-term complication of
operative hysteroscopy in women of reproductive age. TheyTa
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might consider using any barrier gel following operative hys-
teroscopy for suspected uterine cavity abnormalities in infer-
tile women: Its use may decrease de novo adhesion formation
(very low quality evidence). If de novo adhesion formation
occurs, there are less moderate or severe adhesions and more
mild adhesions by using any anti-adhesion gel; the mean
adhesion scores at second-look hysteroscopy are lower after
using ACP gel. Infertile women nevertheless should be
counseled that there is no evidence for higher live birth or
pregnancy rates by using any barrier gel following operative
hysteroscopy (very low-quality evidence). There are no data at
the present of the effects on the miscarriage rates.
Implications for research
The very low-quality evidence retrieved from the limited
number of randomized studies in a general source population
including, but not restricted to, infertile women is at the
present not sufficient to draw robust conclusions in favor of
any barrier as an adjunctive therapy following operative hys-
teroscopy for the key reproductive outcomes; more well-
designed pragmatic RCTs are needed to assess whether the
use of any anti-adhesion gel affects the live birth, the preg-
nancy, and miscarriage rates in a target population of infertile
women. There are no data on a dose–response relationship
between the size, the number, or the severity of the treated
pathology and the corresponding magnitude of the increase in
effectiveness or decrease in the adverse outcomes that were
defined in the present systematic review.
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